List of Excipients in Branded Drug CIMDUO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	CIMDUO	lamivudine and tenofovir disoproxil fumarate	49502-450	CELLULOSE, MICROCRYSTALLINE
Viatris Specialty LLC	CIMDUO	lamivudine and tenofovir disoproxil fumarate	49502-450	CROSCARMELLOSE SODIUM
Viatris Specialty LLC	CIMDUO	lamivudine and tenofovir disoproxil fumarate	49502-450	LACTOSE MONOHYDRATE
Viatris Specialty LLC	CIMDUO	lamivudine and tenofovir disoproxil fumarate	49502-450	MAGNESIUM STEARATE

CIMDUO Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

CIMDUO is a fixed-dose combination tablet containing lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg for HIV-1 treatment in adults and pediatric patients weighing at least 35 kg. Its commercial opportunity is primarily a low-cost, reliable oral solid-dose product rather than a differentiated patent franchise. Excipient suppliers and manufacturers can compete through tablet manufacturability, moisture control, coating efficiency, supply assurance, and lower-cost global formulations.

What is CIMDUO and how is it regulated?

CIMDUO combines two nucleoside reverse transcriptase inhibitor components:

Attribute	CIMDUO detail
Active ingredients	Lamivudine and tenofovir disoproxil fumarate
Strength	300 mg of each active ingredient per tablet
Dosage form	Oral, film-coated tablet
FDA application	NDA 209178
U.S. approval	February 6, 2018
Indication	HIV-1 treatment with other antiretroviral agents
Target population	Adults and pediatric patients weighing at least 35 kg
Prescription status	Prescription-only
PrEP indication	None
Biologic status	Small-molecule product; biosimilar pathway does not apply

The FDA label states that CIMDUO is used with other antiretroviral agents and is not a complete single-tablet regimen by itself. The product contains the same two active ingredients used in several established antiretroviral products, including Epivir and Viread components.[1]

CIMDUO is marketed in a mature antiretroviral category. Commercial value therefore depends on procurement pricing, manufacturing yield, global registration, distributor access, and supply reliability.

What excipients are used in CIMDUO tablets?

The U.S. product labeling identifies a conventional immediate-release tablet excipient system. The listed inactive ingredients include:

• Colloidal silicon dioxide
• Croscarmellose sodium
• Magnesium stearate
• Microcrystalline cellulose
• Povidone
• Sodium starch glycolate
• Film-coating materials, including hypromellose, polyethylene glycol, titanium dioxide and colorant components

The exact excipient composition should be controlled against the current approved product labeling and market-specific dossier because excipient declarations can vary by jurisdiction, manufacturing site, and coating system.[1]

The formulation uses common pharmaceutical excipients rather than a proprietary delivery platform. That reduces formulation barriers for generic and regional manufacturers, but it also limits opportunities to claim meaningful composition-of-matter differentiation.

What does each excipient contribute?

Excipient class	Likely formulation role	Commercial relevance
Microcrystalline cellulose	Filler and compression aid	Supports tablet weight and mechanical strength
Povidone	Binder	Improves granule or tablet cohesion
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup
Sodium starch glycolate	Superdisintegrant	Provides an alternative or complementary disintegration mechanism
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and die filling
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Hypromellose	Film-forming polymer	Provides coating integrity and identification
Polyethylene glycol	Plasticizer	Improves coating flexibility
Titanium dioxide and colorants	Opacity and product identification	Supports appearance and light protection

The formulation challenge is not the novelty of the excipient package. It is balancing high drug loading, tablet strength, disintegration, dissolution, blend uniformity, and moisture control.

What is the optimal excipient strategy for CIMDUO?

The strongest strategy is a robust, low-cost immediate-release platform that supports direct compression or a simple granulation process.

High drug loading and tablet size

CIMDUO contains 600 mg of active pharmaceutical ingredients per tablet before excipients and coating. The total tablet must remain suitable for daily oral administration. Excessive filler increases tablet size and packaging cost, while insufficient filler can impair compression and content uniformity.

Microcrystalline cellulose is commercially attractive because it supports compactability at relatively low use levels. A co-processed cellulose-based excipient could improve flow and compression, but any substitution would require formulation development and comparative dissolution work.

Disintegration and dissolution

The formulation should maintain rapid disintegration despite the high active load. Croscarmellose sodium and sodium starch glycolate can provide complementary swelling and wicking behavior. Their performance depends on particle size, grade, addition method, and compression force.

Over-lubrication with magnesium stearate can reduce tablet wettability and slow dissolution. This is a material process-control risk. Lubricant concentration, blending time, and shear should be optimized rather than treated as fixed parameters.

Moisture and chemical stability

Tenofovir disoproxil fumarate has recognized stability sensitivity, including susceptibility to degradation under unfavorable moisture and temperature conditions. Excipient selection should therefore prioritize low moisture contribution, controlled water activity, and compatibility with the active ingredients.

Key controls include:

• Low-moisture excipient grades
• Moisture-barrier blister or bottle packaging
• Desiccant compatibility
• Controlled granulation water exposure
• Stability testing under ICH long-term and accelerated conditions
• Monitoring of tenofovir-related degradation products

Povidone grade and residual moisture can affect both processing and stability. Suppliers that offer tight moisture specifications, consistent particle-size distribution, and strong change-control systems have a commercial advantage.

Coating system

The coating should provide appearance, handling protection, and product identification without materially delaying dissolution. A standard hypromellose-based coating is adequate for most markets.

Commercial opportunities include:

• Lower-solids coating systems that reduce drying time
• Ready-to-use aqueous coating systems
• Pigment systems that reduce batch variability
• Improved light and moisture protection
• Coatings optimized for high-speed pan operation

A coating change may be commercially useful even when it does not create a new patent position. The value comes from lower manufacturing cost, reduced solvent use, fewer defects, and better supply continuity.

What formulation patents protect CIMDUO?

CIMDUO does not appear to rely on a high-value proprietary excipient platform. The principal active ingredients are mature small molecules, and the core formulation uses standard excipients.

IP category	CIMDUO relevance	Commercial assessment
Lamivudine compound patents	Historical protection	Expired or commercially exhausted in major markets
Tenofovir disoproxil fumarate compound patents	Historical protection	Core protection has largely expired
Fixed-dose combination patents	May exist across historical products	Must be reviewed by jurisdiction and claim scope
CIMDUO-specific formulation patents	No clearly established high-value platform identified from public product information	Low apparent barrier
Manufacturing patents	Possible process-specific claims	Relevant only if claims cover a required process
Method-of-use patents	Limited practical protection for mature HIV treatment use	Low barrier where broad treatment claims have expired
Regulatory exclusivity	Relevant at original approval	Does not create a durable long-term moat

The Orange Book remains the controlling source for current U.S. patent and exclusivity listings associated with the NDA. A patent search should distinguish CIMDUO-specific listings from patents covering lamivudine, tenofovir disoproxil fumarate, other combinations, or unrelated formulations.[2]

When does CIMDUO lose exclusivity?

CIMDUO’s market exclusivity is principally affected by the age of the underlying active ingredients and the availability of alternative fixed-dose combinations.

The key distinction is between FDA regulatory exclusivity and patent exclusivity:

• Lamivudine and tenofovir disoproxil fumarate are mature active ingredients.
• The FDA approval date was February 6, 2018.
• Any new-chemical-entity exclusivity for the active ingredients was unavailable because both ingredients were previously approved.
• Fixed-dose combination approval does not automatically create long-term protection against all products containing the same ingredients.
• Generic or authorized-competitive entry depends on Orange Book listings, ANDA approvals, Paragraph IV certifications, regulatory exclusivity, and litigation outcomes.

CIMDUO’s competitive position is therefore weaker than that of a recently approved single-tablet regimen with active composition patents or a long remaining regulatory exclusivity period.

Are there Paragraph IV challenges to CIMDUO?

A Paragraph IV challenge is possible where an ANDA applicant certifies that listed patents are invalid, unenforceable, or not infringed. The practical risk depends on whether CIMDUO has active Orange Book-listed patents and whether those patents cover the product rather than only historical active-ingredient technology.

Publicly available product information does not establish a durable, CIMDUO-specific Paragraph IV barrier. The relevant commercial conclusion is that generic entry risk is high in a mature market unless an active formulation or method-of-use patent has unusually broad and enforceable claims.

Potential entry routes include:

1. A generic fixed-dose combination containing the same active ingredients.
2. Separate lamivudine and tenofovir disoproxil fumarate products used together.
3. Other branded or generic antiretroviral combinations.
4. Products supplied through public-sector tenders outside the United States.
5. Country-specific products approved under local reliance or abbreviated pathways.

What commercial opportunities exist for excipient suppliers?

Low-moisture excipient platforms

The clearest opportunity is a low-moisture, directly compressible excipient system that reduces stability risk while maintaining tablet hardness and dissolution. Suppliers can create value through:

• Tight loss-on-drying specifications
• Controlled particle-size distribution
• Low microbial burden
• Consistent bulk density
• Validated compatibility data
• Regulatory support for global filings

Co-processed excipients

A co-processed filler-disintegrant or filler-binder system could reduce the number of raw materials and simplify manufacturing. The product would need to demonstrate:

• Improved flow
• Lower compression force
• Acceptable friability
• Rapid disintegration
• Comparable dissolution
• No increase in degradation products

The commercial advantage is strongest for manufacturers producing high volumes under cost pressure.

High-performance lubricants

Alternative lubricants or lower-use-rate magnesium stearate systems can reduce dissolution variability and improve process robustness. This opportunity is technical rather than patent-driven. Suppliers should provide data showing performance across tablet press speeds and compression forces.

Film-coating systems

Ready-to-use coating systems can reduce development time and simplify batch execution. A coating supplier may differentiate through shorter drying cycles, lower defect rates, improved color consistency, or better moisture protection.

Packaging and desiccant systems

Packaging is part of the excipient and stability strategy even though it is not an excipient. High-barrier bottles, desiccant-integrated closures, and moisture-resistant blisters can extend shelf life and reduce degradation risk. This creates an opportunity for contract packagers and primary-packaging suppliers.

How does CIMDUO compare with competing HIV products?

Product category	Active ingredients	Differentiation	CIMDUO competitive position
CIMDUO	Lamivudine/TDF	Two-drug backbone	Low-cost, mature combination
Truvada	Emtricitabine/TDF	HIV treatment and historical PrEP use	Stronger brand recognition and broader historical use
Epzicom	Abacavir/lamivudine	Alternative nucleoside backbone	Different safety and testing considerations
Biktarvy	Bictegravir/emtricitabine/TAF	Single-tablet integrase regimen	More modern regimen and stronger branded positioning
Genvoya	Elvitegravir/cobicistat/emtricitabine/TAF	Single-tablet regimen	More complex formulation and pharmacokinetic profile
Generic TDF/lamivudine products	Lamivudine/TDF	Price and tender access	Direct commercial competition

CIMDUO may remain relevant in price-sensitive markets, public procurement, and treatment programs that use a two-drug nucleoside backbone with another antiretroviral agent. It is less differentiated in developed markets where single-tablet integrase-inhibitor regimens dominate prescribing.

What is the revenue exposure for CIMDUO?

CIMDUO revenue is generally not disclosed as a separate line item in public company reporting. Products in this category are commonly aggregated within broader HIV, generics, or emerging-markets portfolios.

Revenue exposure is driven by:

• Government and institutional procurement
• Generic price erosion
• Availability of competing fixed-dose combinations
• Country registration breadth
• Treatment guideline preference
• Supply continuity
• Manufacturing cost per tablet

The product is unlikely to support premium pricing based on excipient differentiation alone. A supplier or manufacturer should instead target annual-volume contracts, dual sourcing, low-cost production, and regulatory coverage across multiple jurisdictions.

What manufacturing and geographic barriers exist?

The active ingredients are widely known, but commercial execution still requires control of several barriers:

• Consistent API quality and impurity profiles
• High drug-load tablet compression
• Moisture-sensitive stability control
• Bioequivalence or comparative dissolution evidence
• GMP compliance
• Country-specific excipient acceptability
• Packaging qualification
• Pharmacovigilance and product-quality systems
• Tender registration and local supply requirements

The strongest geographic opportunities are likely in markets where HIV treatment procurement emphasizes affordability and where older nucleoside backbones remain included in national or institutional formularies. The United States is more exposed to generic price competition and substitution, while lower- and middle-income markets may place greater value on stable supply and low unit cost.

What litigation and settlement issues affect CIMDUO?

No major, product-defining CIMDUO patent litigation or settlement agreement is established by the core public product information reviewed here. Historical litigation around lamivudine, tenofovir, tenofovir disoproxil fumarate, and related combination products may still be relevant to freedom-to-operate analysis, but it should not be attributed automatically to CIMDUO.

A current legal review should separate:

• Patents listed against CIMDUO’s NDA
• Patents listed against Truvada or other related products
• Process patents covering API manufacture
• Formulation patents covering other strengths or combinations
• Settlement agreements governing specific generic applicants
• Country-specific litigation outside the United States

Key Takeaways

• CIMDUO is a mature fixed-dose lamivudine/tenofovir disoproxil fumarate tablet approved by the FDA in 2018.
• The formulation uses standard excipients, including microcrystalline cellulose, povidone, superdisintegrants, colloidal silicon dioxide, magnesium stearate, and a hypromellose-based coating.
• The principal formulation risk is balancing high drug loading, dissolution, tablet strength, and tenofovir-related moisture stability.
• The strongest excipient opportunities are low-moisture direct-compression systems, co-processed excipients, improved lubricants, efficient film coatings, and moisture-barrier packaging.
• CIMDUO has no biosimilar risk because it is a small-molecule product.
• Generic entry risk is high unless active CIMDUO-specific Orange Book patents or regulatory exclusivities remain in force.
• Commercial value is more likely to come from procurement scale, manufacturing efficiency, and geographic reach than from premium formulation pricing.
• Public reporting does not generally isolate CIMDUO revenue, limiting product-specific revenue attribution.

FAQs

Is CIMDUO a generic HIV medicine?

CIMDUO is an FDA-approved fixed-dose combination product containing two mature generic active ingredients. Its commercial positioning is closer to a low-cost combination product than to a newly patented branded regimen.

Can CIMDUO be reformulated with different excipients?

Yes. A reformulation would require assessment of comparative dissolution, stability, content uniformity, tablet performance, and the applicable FDA post-approval or abbreviated regulatory pathway.

Does CIMDUO have biosimilar competition?

No. Biosimilar rules apply to biologic products. CIMDUO contains small-molecule active ingredients and is subject to generic-drug pathways.

Is CIMDUO approved for HIV pre-exposure prophylaxis?

The CIMDUO FDA label does not identify PrEP as an indication. Its labeled use is HIV-1 treatment in combination with other antiretroviral agents.[1]

What is the highest-value IP opportunity around CIMDUO?

The most credible opportunity is a process or formulation improvement that reduces moisture-related degradation, improves high-speed compression, or lowers coating and packaging costs. A broad composition patent based only on conventional excipients would face substantial patentability and freedom-to-operate challenges.

References

1. U.S. Food and Drug Administration. (2018). CIMDUO (lamivudine and tenofovir disoproxil fumarate) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs.
5. World Health Organization. (2023). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring.